These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 1359575)
1. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Charlton CG; Crowell B Pharmacol Biochem Behav; 1992 Oct; 43(2):423-31. PubMed ID: 1359575 [TBL] [Abstract][Full Text] [Related]
2. Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism. Charlton CG; Mack J Mol Neurobiol; 1994; 9(1-3):149-61. PubMed ID: 7888091 [TBL] [Abstract][Full Text] [Related]
3. Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S-adenosylmethionine: a possible role of hypermethylation in parkinsonism. Charlton CG; Crowell B Mol Chem Neuropathol; 1995 Dec; 26(3):269-84. PubMed ID: 8748929 [TBL] [Abstract][Full Text] [Related]
4. Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosylmethionine: a model that may explain the occurrence of depression in Parkinson's disease. Charlton CG Life Sci; 1997; 61(5):495-502. PubMed ID: 9247319 [TBL] [Abstract][Full Text] [Related]
5. S-adenosyl-L-methionine decreases motor activity in the rat: similarity to Parkinson's disease-like symptoms. Crowell BG; Benson R; Shockley D; Charlton CG Behav Neural Biol; 1993 May; 59(3):186-93. PubMed ID: 8503824 [TBL] [Abstract][Full Text] [Related]
7. Effects of L-dopa treatment on methylation in mouse brain: implications for the side effects of L-dopa. Liu XX; Wilson K; Charlton CG Life Sci; 2000; 66(23):2277-88. PubMed ID: 10855949 [TBL] [Abstract][Full Text] [Related]
8. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Shin E; Rogers JT; Devoto P; Björklund A; Carta M Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357 [TBL] [Abstract][Full Text] [Related]
9. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase. Zhao WQ; Latinwo L; Liu XX; Lee ES; Lamango N; Charlton CG Exp Neurol; 2001 Sep; 171(1):127-38. PubMed ID: 11520127 [TBL] [Abstract][Full Text] [Related]
10. The effects of L-dopa on the activity of methionine adenosyltransferase: relevance to L-dopa therapy and tolerance. Benson R; Crowell B; Hill B; Doonquah K; Charlton C Neurochem Res; 1993 Mar; 18(3):325-30. PubMed ID: 8479601 [TBL] [Abstract][Full Text] [Related]
11. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease. Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934 [TBL] [Abstract][Full Text] [Related]
12. Excessive S-adenosyl-L-methionine-dependent methylation increases levels of methanol, formaldehyde and formic acid in rat brain striatal homogenates: possible role in S-adenosyl-L-methionine-induced Parkinson's disease-like disorders. Lee ES; Chen H; Hardman C; Simm A; Charlton C Life Sci; 2008 Dec; 83(25-26):821-7. PubMed ID: 18930743 [TBL] [Abstract][Full Text] [Related]
13. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503 [TBL] [Abstract][Full Text] [Related]
14. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra. Cole DG; Growdon JH; DiFiglia M Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280 [TBL] [Abstract][Full Text] [Related]
15. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia. Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393 [TBL] [Abstract][Full Text] [Related]
16. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease. Wang X; Yang HA; Wang XN; Du YF Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342 [TBL] [Abstract][Full Text] [Related]
17. Quantification of S-adenosylmethionine-induced tremors: a possible tremor model for Parkinson's disease. Lamango NS; Nesby RA; Charlton CG Pharmacol Biochem Behav; 2000 Mar; 65(3):523-9. PubMed ID: 10683494 [TBL] [Abstract][Full Text] [Related]
18. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease. Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071 [TBL] [Abstract][Full Text] [Related]
19. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity. Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]